Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial focus on severe respiratory disorders.Piper Sandler initiated coverage on Upstream Bio with an Overweight rating and a price target of $75.William Blair has also initiated coverage of Upstream Bio with an Outp ...

The price could be right for these stocks.A low share price doesn't necessarily mean a stock is valued attractively. For example, you wouldn't invest in a company that markets oceanfront property in Arizona regardless of how low its share price was. However, prices per share can matter to investors who don't have a lot of cash to put to work.If you're in that group, you're in luck. Three Fool.com contributors have identified what they view as magnificent stocks trading at under $100 to buy in November. Here ...

Astrazeneca (AZN) closed at $71.42 in the latest trading session, marking a +0.38% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.41%. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 0.8%. Heading into today, shares of the pharmaceutical had lost 8.7% over the past month, lagging the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97% in that time. Investors will be eagerly watching for the performanc ...

In the latest trading session, Astrazeneca (AZN) closed at $75.05, marking a -1.12% move from the previous day. This change lagged the S&P 500's daily loss of 0.03%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, added 0.56%. The pharmaceutical's stock has dropped by 2.92% in the past month, exceeding the Medical sector's loss of 4.4% and lagging the S&P 500's gain of 1.39%. The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming ...

Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday. The company agreed with AstraZeneca Plc's AZN Alexion for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson's disease. Monopar will be responsible for all future global development and commercialization activities. Also Read: Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity in Monopar. Future p ...

Core Insights - Eccogene has announced a $60 million payment from AstraZeneca due to the successful achievement of milestones in the development of ECC5004/AZD5004, marking a significant step in its clinical trials [1][2] - The drug ECC5004/AZD5004 is currently undergoing two global Phase 2b trials aimed at treating obesity and type 2 diabetes, targeting participants who are obese or overweight with related comorbidities [1][2] Company Overview - Eccogene is a clinical-stage biopharmaceutical company focused on developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions [4] - The company retains co-development and co-commercialization rights for ECC5004/AZD5004 in China, having previously licensed global rights to AstraZeneca for an upfront payment of $185 million and potential future milestones totaling up to $1.825 billion [2][4] Drug Development and Pipeline - ECC5004/AZD5004 is an oral small molecule GLP-1 receptor agonist that has advanced into Phase 2b clinical trials, which is seen as a validation of Eccogene's translational research platform [2][3] - Eccogene is also advancing a pipeline of next-generation oral therapeutics, including a clinical-stage THR-β agonist and SSAO inhibitor, which may enhance the efficacy of GLP-1 receptor agonists in treating obesity-related comorbidities [3][4] Market Context - The prevalence of obesity and its associated comorbidities affects over one billion people globally, highlighting the urgent need for effective treatments [2] - AstraZeneca emphasizes the importance of rapidly progressing AZD5004 as a novel solution for patients facing interrelated cardiometabolic diseases and the risks associated with type 2 diabetes and obesity [3]

AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for their drug Wainzua (eplontersen) for treating hereditary transthyretin-mediated amyloidosis, commonly called hATTR-PN or ATTRv-PN.If the European Commission approves Wainzua, it will become the only medicine approved for treating ATTRv-PN that can be self-administered monthly via an auto-injector in the European Union.Wainzua was approved by the name of Wai ...

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with p ...

Astrazeneca (AZN) has been beaten down lately with too much selling pressure. While the stock has lost 5.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

AstraZeneca (AZN) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia. The latest agreement is likely to strengthen AstraZeneca's cardiovascular pipeline, which is being studied for treating various cardiovascular diseases. Image Source: Zacks Investment Research Year to date, shares of AstraZeneca have rallied 14.1% compared with the ...